What changed in Bolt Biotherapeutics, Inc.'s 2023 10-K compared to 2022?

Across the narrative sections we track, Bolt Biotherapeutics, Inc. (BOLT) added 0 paragraphs, removed 0, and edited 0 between the 2022 and 2023 10-K filings. The biggest movers are .

Where does this BOLT 10-K diff come from?

The source filings are Bolt Biotherapeutics, Inc.'s official 2022 and 2023 Form 10-K annual reports from SEC EDGAR. 10q10k.net parses each filing, aligns paragraphs by section (Item 1, 1A, 1C, 2, 3, 7, 7A), and highlights every added, removed and edited sentence side-by-side.

Bolt Biotherapeutics, Inc.BOLTEarnings & Financial Report

Nasdaq · Health Care · Pharmaceutical Preparations

Deep Analysis

Bolt Biotherapeutics, Inc. is a clinical-stage biotechnology company specializing in immune-stimulating antibody conjugate (ISAC) therapies for cancer treatment. Its core pipeline targets hard-to-treat solid tumors, serving global oncology markets and advancing novel immunotherapies that trigger targeted anti-tumor immune responses to improve patient outcomes.

What changed in Bolt Biotherapeutics, Inc.'s 10-K — 2022 vs 2023

No meaningful paragraph-level changes detected in the compared sections. Either the two filings are nearly identical or the sections did not parse.

Other BOLT 10-K year-over-year comparisons

BOLT 10-K 2024 vs 2025
BOLT 10-K 2023 vs 2024